BACKGROUND/ OBJECTIVE: Variants in the interleukin-23 receptor (IL23R) and the autophagy-related 16-like 1 (ATG16L1) genes have been associated with an increased risk of Crohn's disease (CD). Both genes were identified through genome-wide association scans and subsequent studies have validated these associations. To assess the effect size of these variants, an independent case-control association study and meta-analysis were performed. METHODS: British Caucasian subjects with inflammatory bowel disease (n=500) and 877 ethnically matched controls were genotyped for the disease-associated variants in IL23R and ATG16L1. In addition, meta-analyses of 12,991 patients and 14,598 controls, and 11,909 patients and 15,798 controls, were conducted on independently published data for the associations between IL23R and ATG16L1 variants and CD, respectively. RESULTS: In the present cohort, both susceptibility variants showed highly significant associations, including IL23R (rs11209026, P=0.0006; OR 0.37; 95% CI 0.21 to 0.67) and ATG16L1 (rs2241880, P=0.0017; OR 1.36; 95% CI 1.12 to 1.66). The meta-analysis based on the random effects model showed similar combined effects for rs11209026 (n=26, OR 0.41; 95% CI 0.37 to 0.46) and rs2241880 (n=25, OR 1.33; 95% CI 1.28 to 1.39). There was no statistically significant gene-gene interaction between caspase recruitment domain (CARD15) variants and the IL23R or ATG16L1 polymorphisms (P=0.44 and P=0.24, respectively). CONCLUSION: The present cohort and meta-analysis provides strong evidence that, in addition to CARD15, polymorphisms in both IL23R and ATG16L1 alter susceptibility to CD and that these effects are consistent across all populations of European ancestry; however, only ATG16L1 is relevant to inflammatory bowel disease in the Asian population.
BACKGROUND/ OBJECTIVE: Variants in the interleukin-23 receptor (IL23R) and the autophagy-related 16-like 1 (ATG16L1) genes have been associated with an increased risk of Crohn's disease (CD). Both genes were identified through genome-wide association scans and subsequent studies have validated these associations. To assess the effect size of these variants, an independent case-control association study and meta-analysis were performed. METHODS: British Caucasian subjects with inflammatory bowel disease (n=500) and 877 ethnically matched controls were genotyped for the disease-associated variants in IL23R and ATG16L1. In addition, meta-analyses of 12,991 patients and 14,598 controls, and 11,909 patients and 15,798 controls, were conducted on independently published data for the associations between IL23R and ATG16L1 variants and CD, respectively. RESULTS: In the present cohort, both susceptibility variants showed highly significant associations, including IL23R (rs11209026, P=0.0006; OR 0.37; 95% CI 0.21 to 0.67) and ATG16L1 (rs2241880, P=0.0017; OR 1.36; 95% CI 1.12 to 1.66). The meta-analysis based on the random effects model showed similar combined effects for rs11209026 (n=26, OR 0.41; 95% CI 0.37 to 0.46) and rs2241880 (n=25, OR 1.33; 95% CI 1.28 to 1.39). There was no statistically significant gene-gene interaction between caspase recruitment domain (CARD15) variants and the IL23R or ATG16L1 polymorphisms (P=0.44 and P=0.24, respectively). CONCLUSION: The present cohort and meta-analysis provides strong evidence that, in addition to CARD15, polymorphisms in both IL23R and ATG16L1 alter susceptibility to CD and that these effects are consistent across all populations of European ancestry; however, only ATG16L1 is relevant to inflammatory bowel disease in the Asian population.
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant Journal: Inflamm Bowel Dis Date: 2008-11 Impact factor: 5.325
Authors: R K Weersma; P C F Stokkers; A A van Bodegraven; R A van Hogezand; H W Verspaget; D J de Jong; C J van der Woude; B Oldenburg; R K Linskens; E A M Festen; G van der Steege; D W Hommes; J B A Crusius; C Wijmenga; I M Nolte; G Dijkstra Journal: Gut Date: 2008-09-29 Impact factor: 23.059
Authors: Anna Latiano; Orazio Palmieri; Maria Rosa Valvano; Renata D'Incà; Salvatore Cucchiara; Gabriele Riegler; Anna Maria Staiano; Sandro Ardizzone; Salvatore Accomando; Gian Luigi de Angelis; Giuseppe Corritore; Fabrizio Bossa; Vito Annese Journal: World J Gastroenterol Date: 2008-08-07 Impact factor: 5.742
Authors: Jürgen Glas; Julia Seiderer; Martin Wetzke; Astrid Konrad; Helga-Paula Török; Silke Schmechel; Laurian Tonenchi; Christine Grassl; Julia Dambacher; Simone Pfennig; Kerstin Maier; Thomas Griga; Wolfram Klein; Jörg T Epplen; Uwe Schiemann; Christian Folwaczny; Peter Lohse; Burkhard Göke; Thomas Ochsenkühn; Bertram Müller-Myhsok; Matthias Folwaczny; Thomas Mussack; Stephan Brand Journal: PLoS One Date: 2007-09-05 Impact factor: 3.240
Authors: Kristina Gruden; Matjaž Hren; Ana Herman; Andrej Blejec; Tanja Albrecht; Joachim Selbig; Chris Bauer; Johannes Schuchardt; Michal Or-Guil; Klemen Zupančič; Urban Svajger; Borut Stabuc; Alojz Ihan; Andreja Nataša Kopitar; Maja Ravnikar; Miomir Knežević; Primož Rožman; Matjaž Jeras Journal: PLoS One Date: 2012-01-12 Impact factor: 3.240
Authors: Jee Hye Kwon; Jong Pil Im; Byong Duk Ye; Jae Hee Cheon; Hyun Joo Jang; Kang Moon Lee; You Sun Kim; Sang Wook Kim; Young Ho Kim; Geun Am Song; Dong Soo Han; Won Ho Kim; Joo Sung Kim Journal: Gut Liver Date: 2016-07-15 Impact factor: 4.519